The biotech company reported second-quarter financial results on Friday ahead of market open, a day after announcing plans to ...

"Moderna sharpens focus on $1.5bn cost cutting plan after 41% revenue slump" was originally created and published by ...

(NASDAQ:MRNA) today reported financial results and provided business updates for the second quarter of 2025. "In the last three months, we advanced our pipeline with positive Phase 3 flu vaccine ...

Despite a net loss, Moderna Inc (MRNA) showcases resilience with significant cost cuts, new FDA approvals, and a robust cash ...

Biotech firm aims to streamline operations and reinvest in high-growth areas such as oncology and rare diseases as it targets ...

US mRNA specialist Moderna has today reported financial results and provided business updates for the second quarter of 2025, ...

Biotech giant Moderna announced it will lay off 10% of its workforce in a move CEO Stéphane Bancel called “a difficult ...

Moderna reduced its 2025 revenue forecast due to deferred UK vaccine deliveries. Despite a smaller-than-expected quarterly loss, its shares fell 7%. The company faces challenges from declining ...

Shares of Moderna fell sharply Friday after the company lowered the top end of its full-year revenue outlook because of a ...

Moderna Inc. said it will reduce its global workforce by roughly 10% before year’s end, responding to sharply reduced demand ...

Analysts have given Moderna a total of 6 ratings, with the consensus rating being Neutral. The average one-year price target ...

In a memo, CEO Stéphane Bancel said the job cuts are needed to align the struggling vaccine maker’s cost structure with the ...